KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Biogen (BIIB) EBIT Margin (2016 - 2025)

Biogen (BIIB) has 17 years of EBIT Margin data on record, last reported at 55.62% in Q4 2025.

  • For Q4 2025, EBIT Margin rose 18.0% year-over-year to 55.62%; the TTM value through Dec 2025 reached 35.81%, up 2290.0%, while the annual FY2025 figure was 57.22%, 2672.0% up from the prior year.
  • EBIT Margin reached 55.62% in Q4 2025 per BIIB's latest filing, up from 4.62% in the prior quarter.
  • Across five years, EBIT Margin topped out at 55.62% in Q4 2025 and bottomed at 31.65% in Q3 2023.
  • Average EBIT Margin over 5 years is 18.48%, with a median of 19.49% recorded in 2021.
  • Peak YoY movement for EBIT Margin: crashed -6759bps in 2023, then soared 5818bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 21.48% in 2021, then crashed by -94bps to 1.29% in 2022, then crashed by -2547bps to 31.65% in 2023, then soared by 275bps to 55.45% in 2024, then rose by 0bps to 55.62% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 55.62% in Q4 2025, 4.62% in Q3 2025, and 40.01% in Q2 2025.